Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About
This story raises questions about governance, accountability, and American values.
The mainstream framing here treats Trump’s interest in psychedelics as a market signal, as if a headline endorsement is the same thing as a settled public policy. It also assumes that “innovation” automatically means progress, and that investors should follow the political scent trail. That skips the conservative worry: medicine is not a meme stock.
New Republican Times Editorial Board
Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.
Original source:
Read at FoolHow We See It
New Republican Times Editorial Board
The mainstream framing here treats Trump’s interest in psychedelics as a market signal, as if a headline endorsement is the same thing as a settled public policy. It also assumes that “innovation” automatically means progress, and that investors should follow the political scent trail.
That skips the conservative worry: medicine is not a meme stock. If Compass Pathways is truly in late stage development, the question is whether the data hold up and whether the rollout protects patients, not whether the politics are fashionable. Public trust in health institutions is already thin, and hype makes it thinner.
A serious approach means rule-of-law regulation, transparent trials, and accountability for adverse outcomes. It also means guarding against regulatory capture and profiteering that leaves families with the risks and companies with the upside.
In the end, this is about institutional stability: treatments should earn legitimacy through evidence and oversight, not through headlines.
Commentary written with AI assistance by the New Republican Times Editorial Board.